New York State Common Retirement Fund purchased a new stake in Calithera Biosciences, Inc. (NASDAQ:CALA) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 32,700 shares of the biotechnology company’s stock, valued at approximately $486,000. New York State Common Retirement Fund owned 0.09% of Calithera Biosciences at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in CALA. FMR LLC grew its position in Calithera Biosciences by 278.2% in the first quarter. FMR LLC now owns 1,462,190 shares of the biotechnology company’s stock valued at $16,888,000 after acquiring an additional 1,075,592 shares during the period. Vanguard Group Inc. grew its position in Calithera Biosciences by 99.8% in the first quarter. Vanguard Group Inc. now owns 925,015 shares of the biotechnology company’s stock valued at $10,684,000 after acquiring an additional 462,137 shares during the period. Acadian Asset Management LLC grew its position in Calithera Biosciences by 608.7% in the second quarter. Acadian Asset Management LLC now owns 233,956 shares of the biotechnology company’s stock valued at $3,474,000 after acquiring an additional 200,946 shares during the period. TIAA CREF Investment Management LLC bought a new stake in Calithera Biosciences in the second quarter valued at $2,727,000. Finally, Goldman Sachs Group Inc. grew its position in Calithera Biosciences by 729.7% in the first quarter. Goldman Sachs Group Inc. now owns 133,981 shares of the biotechnology company’s stock valued at $1,547,000 after acquiring an additional 117,832 shares during the period. Hedge funds and other institutional investors own 71.88% of the company’s stock.

In other Calithera Biosciences news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the business’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $15.64, for a total value of $9,008,640.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. 16.30% of the stock is currently owned by insiders.

A number of brokerages have weighed in on CALA. BidaskClub cut Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Monday, November 6th. Finally, William Blair began coverage on Calithera Biosciences in a research report on Thursday, October 5th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $15.17.

COPYRIGHT VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/11/14/new-york-state-common-retirement-fund-purchases-shares-of-32700-calithera-biosciences-inc-cala.html.

Calithera Biosciences, Inc. (CALA) opened at $11.72 on Tuesday. Calithera Biosciences, Inc. has a one year low of $2.90 and a one year high of $20.05.

Calithera Biosciences (NASDAQ:CALA) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The business had revenue of $7.20 million during the quarter, compared to analyst estimates of $6.02 million. research analysts anticipate that Calithera Biosciences, Inc. will post -0.77 EPS for the current fiscal year.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Stock Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related stocks with our FREE daily email newsletter.